Rallybio (RLYB, Financial) is advancing its lead therapeutic candidate, RLYB116, into a critical pharmacokinetic and pharmacodynamic study within this quarter. The company anticipates that results from this research will highlight RLYB116’s potential to be a leading treatment option for patients suffering from complement-driven diseases. With a team experienced in the complement field, Rallybio is confident in harnessing RLYB116’s capabilities to tap into various lucrative market segments.
In addition to RLYB116, Rallybio is focusing on its preclinical pipeline, which includes promising candidates REV102 and RLYB332. By progressing these innovative treatments, Rallybio aims to generate substantial value for its shareholders and deliver impactful therapies to patients requiring such medical advancements.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Rallybio Corp (RLYB, Financial) is $1.00 with a high estimate of $1.00 and a low estimate of $1.00. The average target implies an upside of 232.67% from the current price of $0.30. More detailed estimate data can be found on the Rallybio Corp (RLYB) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, Rallybio Corp's (RLYB, Financial) average brokerage recommendation is currently 2.8, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
